GM proponents grill German government

German GM proponents have taken action against discrimination of food products generated by gene editing.

Read more

New CEO for Valo Therapeutics

Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already served as part-time co-Chairman since the company’s inception in 2017.

Read more

IL-10R-deficient macrophages trigger IBD

Researchers from Israel and the UK have identified how the cytokine IL-23 triggers inflammatory bowel syndrome (IBD), which affects 1.6 million patients annually in the US alone.

Read more

Machine learning for high-content analysis: User stories

Scientists from the University of Washington are using the Phenoglyphs machine learning module to achieve faster high-content analysis through automation and simplification.

Read more

Breakthrough in liquid biopsy

German and US researchers have developed a diagnostic technique capable to detect one single circulating tumour cell in one litre of blood.

Read more

ADC Therapeutics raise $76m in Series E expansion

Swiss antibody drug conjugate developer ADC Therapeutics SA raised $76m, bringing the total gross proceeds to $276 million in its Series E financing.

Read more

Evotec bags US$23.8m to fight tuberculosis

The Bill & Melinda Gates Foundation has granted Evotec SE $23.8m to identify the best drug combos to fight tuberculosis.

Read more

How lungs trigger innate lymphoid cell dynamics

The cells’ surrounding structures play an important role as cues from the immune system in guiding their motility and behaviour, researchers from the UK and the US report.

Read more

Researchers find clue to Parkinson’s gene therapy

An enzyme that clears out alpha-synuclein from neurons may counteract Parkinson’s Disease, report researchers from ETH Zürich and Novartis.

Read more

Chikungunya vaccine developer Themis bags $21m

Under a partnering ageement with CEPI, Themis Bioscience will receive $21m to push pivotal testing of MV-CHIK, its Chikungunya vaccine candidate.

Read more